{"nctId":"NCT00046891","briefTitle":"EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer","startDateStruct":{"date":"2002-12"},"conditions":["Breast Cancer","Neurotoxicity"],"count":226,"armGroups":[{"label":"Ginkgo Biloba","type":"EXPERIMENTAL","interventionNames":["Drug: Ginkgo Biloba"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Ginkgo Biloba","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Newly diagnosed breast cancer\n* Planned standard doses of adjuvant chemotherapy with or without a taxane\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Any status\n\nPerformance status\n\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n\nLife expectancy\n\n* At least 6 months\n\nHematopoietic\n\n* No bleeding diathesis\n\nHepatic\n\n* serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase no greater than 1.5 times ULN\n\nRenal\n\n* Creatinine no greater than 1.5 times ULN\n\nCardiovascular\n\n* No arterial vascular disease\n\nOther\n\n* Able to complete questionnaires alone or with assistance\n* No diabetes\n* No dementia\n* No diagnosis of a psychiatric disorder within the past 5 years that would preclude study compliance\n* No other significant comorbidity\n* No known allergy to ginkgo biloba\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No concurrent stem cell transplantation\n\nChemotherapy\n\n* No concurrent high-dose chemotherapy\n\nOther\n\n* More than 6 months since prior EGb761\n* No concurrent antithrombotic therapy (e.g., daily aspirin or anticoagulants)\n\n  * Anticoagulants used for central or peripheral line maintenance (i.e., warfarin 1 mg/day or heparin flushes) allowed\n* No concurrent dose-intensive regimens\n* No concurrent aspirin or aspirin-like medicines (e.g., indomethacin, ibuprofen, or some antihistamines or heparin or warfarin \\[except as used above\\])\n* No concurrent regimen expected to cause thrombocytopenia\n* No concurrent trazodone, monoamine oxidase inhibitors, or thiazide diuretics (e.g., chlorothiazide, hydrochlorothiazide, indapamide, or metolazone)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score.","description":"The primary analysis involved compiling each subscale score for the HSCS into area under the curve (AUC) scores for the data points from baseline to the 12 month data point. HSCS instrument contains questions regarding Memory (0-39), Language (0-30), Visual-motor (0-10), Spatial (0-8), Attention and Concentration (0-25), Self-Regulation and Planning (0-6) on a varying scales. Total is calculated by summing afore mentioned subscales, values of Total ranged from 0 to 125. Lower scores are better.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"9.18"},{"groupId":"OG001","value":"12.6","spread":"9.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"6.84"},{"groupId":"OG001","value":"2.6","spread":"2.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.29"},{"groupId":"OG001","value":"0.7","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.92"},{"groupId":"OG001","value":"1.3","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"3.59"},{"groupId":"OG001","value":"1.8","spread":"2.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.14"},{"groupId":"OG001","value":"2.0","spread":"2.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":"19.59"},{"groupId":"OG001","value":"18.0","spread":"12.26"}]}]}]},{"type":"SECONDARY","title":"Median Scores for Trail Making Tests A and B (Lower Scores Are Better).","description":"The Trail Making Test is a measure of overall brain dysfunction. Time taken to complete TMT tests was recorded. For this analysis median values of the Trail Making tests are calculated at different time points.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Measure of Cognitive Function Using Trail Making Tests (TMT) A and B.","description":"TMT A and B were analyzed by evaluating median changes from baseline to different time points. Lower scores are better. The Trail Making Test will provide additional validity and verification for the assessment of overall cognitive dysfunction. Abbreviations used for category titles in the table below: Baseline (BL), change (chg), month (mth).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":null},{"groupId":"OG001","value":"-4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":null},{"groupId":"OG001","value":"-6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"-5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":null},{"groupId":"OG001","value":"-8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"-2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7","spread":null},{"groupId":"OG001","value":"-3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":null},{"groupId":"OG001","value":"-4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7","spread":null},{"groupId":"OG001","value":"-9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7","spread":null},{"groupId":"OG001","value":"-5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"-7","spread":null}]}]}]},{"type":"SECONDARY","title":"Self-reported Symptoms or Side Effects Using Symptom Experience Diary (SED)","description":"Self-reported symptoms or side effects mean change from baseline to 1st post chemo visit (negative numbers indicate worsening symptoms). A descriptive report of the toxicities experienced by participants will be measured with a Symptom Experience Diary. Participants will complete this questionnaire. This patient diary contains several questions related to potential side effects and side benefits of Ginko Biloba measured on a numeric analogue scale (based on 0-10 scale with 10 being worst toxicity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.90"},{"groupId":"OG001","value":"-0.8","spread":"2.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.78"},{"groupId":"OG001","value":"-0.9","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.96"},{"groupId":"OG001","value":"-0.3","spread":"2.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.77"},{"groupId":"OG001","value":"-0.9","spread":"2.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.13"},{"groupId":"OG001","value":"-1.2","spread":"2.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.74"},{"groupId":"OG001","value":"0.0","spread":"2.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"2.61"},{"groupId":"OG001","value":"-0.4","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.33"},{"groupId":"OG001","value":"-0.9","spread":"2.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.08"},{"groupId":"OG001","value":"-0.6","spread":"2.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.82"},{"groupId":"OG001","value":"-0.5","spread":"3.06"}]}]}]},{"type":"SECONDARY","title":"Associations Between Self-reported Cognition and the HSCS.","description":"Pearson correlation coefficients conceptually related objective HSCS and subjective self-reported cognition. For this analysis data from both arms are combined. In the table below, numbers closer to 1 indicate positive correlation; numbers closer to -1 indicate negative correlation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.08","spread":null},{"groupId":"OG002","value":"-0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"-0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":null},{"groupId":"OG001","value":"0.02","spread":null},{"groupId":"OG002","value":"-0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.07","spread":null},{"groupId":"OG002","value":"-0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":null},{"groupId":"OG001","value":"-0.07","spread":null},{"groupId":"OG002","value":"-0.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Associations Between Self-report Measures of Cognition and the Trail Making Test (TMT) A and B.","description":"Pearson correlation coefficients conceptually related objective TMT A and B and subjective self-report measures of cognition. For this analysis data from both arms are combined. In the table below, numbers closer to 1 indicate positive correlation; numbers closer to -1 indicate negative correlation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":null},{"groupId":"OG001","value":"0.05","spread":null},{"groupId":"OG002","value":"-0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":".20","spread":null},{"groupId":"OG002","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":null},{"groupId":"OG001","value":"0.03","spread":null},{"groupId":"OG002","value":"-0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.08","spread":null},{"groupId":"OG002","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":null},{"groupId":"OG001","value":"-0.02","spread":null},{"groupId":"OG002","value":"-0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":null},{"groupId":"OG001","value":"-0.02","spread":null},{"groupId":"OG002","value":"-0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.28","spread":null},{"groupId":"OG002","value":"0.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.08","spread":null},{"groupId":"OG002","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"-.05","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":104},"commonTop":["Hemoglobin decreased","Nausea","Leukocyte count decreased","Vomiting","Platelet count decreased"]}}}